Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03151746|
Recruitment Status : Recruiting
First Posted : May 12, 2017
Last Update Posted : January 24, 2018
The study's objective is to determine the efficacy of preoperative gabapentin in relieving postoperative pain, reducing opioid use and improving quality of recovery in subjects undergoing urologic surgery.
Investigators hypothesize that subjects receiving gabapentin will have lower pain scores, less opioid consumption and better quality of recovery as compared to subjects who are given a placebo.
|Condition or disease||Intervention/treatment||Phase|
|Anesthesia Urethral Obstruction||Drug: Placebo Drug: Gabapentin||Phase 4|
Approximately one hour prior to induction of anesthesia in preoperative holding area all enrolled subjects will receive PO Acetaminophen 650 mg, the Gabapentin group will receive PO Gabapentin 1200 mg, while the Control group will receive PO Placebo, with a small amount of water.
Upon arrival in the operating room, standard ASA monitors will be applied. Intraoperative, patients will receive a standardized anesthetic care. This care consists of induction with IV propofol 2mg/kg, IV fentanyl 2 mcg/kg (adjusted body weight), and IV rocuronium 0.6 mg/kg for tracheal intubation or IV succinylcholine 1mg/kg if rapid sequence induction is needed.
For maintenance of general anesthesia, investigators will use Sevoflurane, with the goal to maintain BP within 20% of preoperative baseline and BIS 40-60.
If HR > 100/min and BIS 40-60 may use IV esmolol 0.5 mg/kg. If BP and/or HR >20% preoperative baseline, and BIS 40- 60 despite above management, may titrate IV antihypertensive agents.
For PONV prophylaxis, 30 min before end of surgery investigatorswill administer IV ondansetron 8mg.
The time from end of surgery to extubation in OR will be documented with a free text note in the EMR.
After extubation all patients will be transported to PACU on 2-liter Oxygen by nasal cannula, which will be weaned off in the PACU.
The postoperative analgesics during Phase I of recovery in PACU will consist of IV Hydromorphone 0.2-0.4 mg prn pain to maintain adequate pain control (NPRS<4). During Phase II of recovery patients will receive PO Hydromorphone 2mg tablets every 4-6 hours as needed for pain (NPRS ≥ 4) and acetaminophen: 650mg PO every 6 hours
The following data will be collected every hour during phase I and phase II recovery:
- pain (NPRS)
- sedation (Ramsey sedation scale)
- dizziness (1- mild, 2- moderate, 3- severe)
- headache YES/No If yes: NPRS score HA
- respiratory depression (hypoventilation/ apnea: RR < 10 bpm., desaturation: (SpO2 < 90%)
- Sedated but still in pain (Yes/No)
- PONV YES/NO
- PONV receiving antiemetic treatment
- time to first opioid administration (IV hydromorphone)
- total amount of IV hydromorphone in PACU Phase I
- total amount of oral analgesic (hydromorphone) in PACU Phase II
- time to meet discharge criteria from PACU Phase I
- time to meet discharge criteria from Phase II
Study research personnel will contact participants by phone or in the hospital at 24 hours and 48 hours postoperative and at approximately one week in the Urology clinic. The study research personnel will ask questions regarding pain (NPRS) and analgesic consumption. The IPSS and QOR-40 questionnaires will be administered and data will be recorded.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Double Blind, Randomized, Placebo Controlled Trial|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Blinded by using placebo or active drug supplied by Investigational Drug Pharmacy.|
|Official Title:||Effect of Preoperative Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion: a Double Blind, Randomized, Placebo Controlled Trial|
|Actual Study Start Date :||January 14, 2018|
|Estimated Primary Completion Date :||December 2019|
|Estimated Study Completion Date :||January 2020|
Placebo Comparator: Placebo
Placebo pill administered 1 hour before planned surgical procedure
Placebo pill administered orally 1 hour before planned surgical procedure
Gabapentin pill (1200mg) administered orally 1 hour prior to planned surgical procedure
Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
- 48 hours opioid consumption [ Time Frame: 48 hours ]Amount of opioid use in mg 48 hours after surgical procedure
- 24 hours opioid consumption [ Time Frame: 24 hours ]Amount of opioid use in mg 24 hours opioid consumption
- 24 & 48 hour Pain Burden [ Time Frame: 24 and 48 hours ]Pain scores using an 11 point numeric pain rating scale 0=no pain 10 = severe pain
- Study drug side effects [ Time Frame: 24 and 48 hours ]Gabapentin related side effects as identified at 24, 48 hours
- IPSS scores [ Time Frame: 24 hours, 48 hours and 1 week ]Evaluate urinary symptoms using the International Prostate Symptom Score (IPSS)
- QOR 40 scores [ Time Frame: 24 hours, 48 hours and 1 week ]Evaluate quality of recovery using the Quality of Recovery 40 (QoR 40) questionnaire a 40 question survey scored from 40 low to 200 high (good recovery)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03151746
|Contact: Luminita Turneau, M.D.||email@example.com|
|Contact: Robert McCarthy, PharmDfirstname.lastname@example.org|
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Contact: Luminita Turneau, M.D. 312-695-0061 email@example.com|
|Contact: Robert McCarthy, PharmD 312-695-4976 firstname.lastname@example.org|
|Principal Investigator:||Luminita Turneau, M.D.||Northwestern University|